GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Cyclically Adjusted PS Ratio

Dynavax Technologies (FRA:DYF1) Cyclically Adjusted PS Ratio : 9.10 (As of Jun. 09, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted PS Ratio?

As of today (2024-06-09), Dynavax Technologies's current share price is €11.105. Dynavax Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €1.22. Dynavax Technologies's Cyclically Adjusted PS Ratio for today is 9.10.

The historical rank and industry rank for Dynavax Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:DYF1' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.18   Med: 6.3   Max: 37.42
Current: 9.07

During the past years, Dynavax Technologies's highest Cyclically Adjusted PS Ratio was 37.42. The lowest was 1.18. And the median was 6.30.

FRA:DYF1's Cyclically Adjusted PS Ratio is ranked worse than
92.06% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.05 vs FRA:DYF1: 9.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dynavax Technologies's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.359. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €1.22 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Dynavax Technologies Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted PS Ratio Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.87 9.17 22.09 9.45 10.89

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.40 10.80 12.00 10.89 9.33

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted PS Ratio falls into.



Dynavax Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Dynavax Technologies's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=11.105/1.22
=9.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dynavax Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dynavax Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.359/131.7762*131.7762
=0.359

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.085 100.560 0.111
201409 0.065 100.428 0.085
201412 0.070 99.070 0.093
201503 0.021 99.621 0.028
201506 0.047 100.684 0.062
201509 0.029 100.392 0.038
201512 0.019 99.792 0.025
201603 0.022 100.470 0.029
201606 0.061 101.688 0.079
201609 0.004 101.861 0.005
201612 0.179 101.863 0.232
201703 0.003 102.862 0.004
201706 0.002 103.349 0.003
201709 0.001 104.136 0.001
201712 0.000 104.011 0.000
201803 0.002 105.290 0.003
201806 0.017 106.317 0.021
201809 0.020 106.507 0.025
201812 0.075 105.998 0.093
201903 0.080 107.251 0.098
201906 0.113 108.070 0.138
201909 0.128 108.329 0.156
201912 0.113 108.420 0.137
202003 0.115 108.902 0.139
202006 0.024 108.767 0.029
202009 0.102 109.815 0.122
202012 0.146 109.897 0.175
202103 0.617 111.754 0.728
202106 0.369 114.631 0.424
202109 0.787 115.734 0.896
202112 0.916 117.630 1.026
202203 0.693 121.301 0.753
202206 1.618 125.017 1.705
202209 1.118 125.227 1.176
202212 1.147 125.222 1.207
202303 0.343 127.348 0.355
202306 0.366 128.729 0.375
202309 0.422 129.860 0.428
202312 0.394 129.419 0.401
202403 0.359 131.776 0.359

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dynavax Technologies  (FRA:DYF1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Dynavax Technologies Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (FRA:DYF1) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines